SPORE in Prostate Cancer

描述(由申请人提供)： 前列腺癌卓越研究(孢子)专业计划，网址： 梅奥诊所综合癌症中心将支持多学科 基础、临床和人口科学研究人员团队将执行 旨在显著降低死亡率的翻译研究 前列腺癌。唐纳德·J·廷德尔博士将担任校长 调查员。医学博士Michael M.Liebet将担任联席校长 调查员。孢子的翻译研究目标将是 由六个研究项目指导：项目1：人类的遗传易感性 前列腺癌(Stephen N.Thibodeau，Ph.D.，Michael L.Blute，M.D.，Daniel 首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容 博士学位)项目2：人类激肽释放酶作为前列腺癌的新标记物 (Charles Y.F.Young，George G.Klee，M.D.，Ph.D.Donald J.Tindall，Ph.D. Michael Liebet，医学博士)。项目3：红豆杉的生物学和临床研究 8q24区域过度表达与前列腺癌进展相关 (罗伯特·B·詹金斯医学博士、迈克尔·M·利贝特医学博士)项目4：一个 前列腺癌的免疫治疗方法(Esteban Celis，M.D.， 博士，Patrick A.Burch，M.D.)项目5：使用镰刀菌膜 前列腺癌基因治疗中的糖蛋白(Richard G.Vile，Ph.D.， 医学博士伊万西亚·加拉希斯、医学博士布莱恩·J·戴维斯、医学博士托兰斯·威尔逊)。项目 6：使用放射性碘进行前列腺癌的基因治疗(约翰·C·莫里斯 III，M.D.，Brian J.Davis，M.D.，Esteban Celis，M.D.，Richard G.Vile，Ph.D.) 五个核心资源将支持这些研究项目：核心1： 行政核心(Donald J.Tindall博士)。核心2：前列腺癌 组织资源核心(John C.Cheville，M.D.，Patrick Roche，Ph.D.)。核心3： 基因发现和生物信息学核心(George Vasmatzis，Ph.D.，Stephen J. 伊图里亚，博士)。核心4：临床随访核心(Brian J.Davis，M.D.，Mike Blute M.D.，Patrick A.Burch，M.D.，Thomas M.Pisansky，M.D.)核心5： 生物统计学核心(Daniel J.Sargent，Ph.D.，Susan Geyer，Ph.D.，Erik J. Bergstrahl，M.S.)。已经建立了一个发展研究计划来 探索创新研究和职业发展计划的机会 已经被组织起来，以帮助年轻的调查人员建立独立 在前列腺癌的转化研究中。孢子结构提供了 集中和整合调查人员发现工作的理想机制 并优化利用梅奥诊所的临床资源，以 在前列腺癌的管理方面取得有意义的进展。

DESCRIPTION (provided by applicant): This Specialized Program of Research Excellence (SPORE) in prostate cancer at the Mayo Clinic Comprehensive Cancer Center will support a multidisciplinary team of basic, clinical, and population science investigators to perform translational research directed at significantly reducing mortality from prostate carcinoma. Donald J. Tindall, Ph.D. will serve as the Principal Investigator. Michael M. Liebet, M.D. will serve as Co-Principal Investigator. The translational research objectives of the SPORE will be directed by six research projects: Project 1: Genetic Susceptibility in Prostate Cancer (Stephen N. Thibodeau, Ph.D., Michael L. Blute, M.D., Daniel J. Schaid, Ph.D., James R. Cerhan: M.D., Ph.D., Steven J. Jacobsen, M.D., Ph.D.) Project 2: Human Kallikreins as Novel Markers of Prostate Cancer (Charles Y.F. Young, George G. Klee, M.D., Ph.D. Donald J. Tindall, Ph.D., Michael Liebet, M.D.). Project 3: Biologic and Clinical Studies of the Over-represented 8q24 Region Associated with Prostate Cancer Progression (Robert B. Jenkins, M.D., Ph.D., Michael M. Liebet, M.D.). Project 4: An Immune-Based Therapeutic Approach for Prostate Cancer, (Esteban Celis, M.D., Ph.D., Patrick A. Burch, M.D.,). Project 5: Use of Fusogeoic Membrane Glycoproteins for Gene Therapy of Prostate Cancer (Richard G. Vile, Ph.D., Evanthia Galahis, M.D., Brian J. Davis, M.D., Torrance Wilson, M.D.). Project 6: Gene Therapy of Prostate Cancer using Radioactive Iodine (John C. Morris III, M.D., Brian J. Davis, M.D., Esteban Celis, M.D., Richard G. Vile, Ph.D.). Five core resources will support these research projects: Core 1: Administrative Core (Donald J. Tindall, Ph.D.). Core 2: Prostate Cancer Tissue Resource Core (John C. Cheville, M.D., Patrick Roche, Ph.D.). Core 3: Gene Discovery and Bioinformatics Core (George Vasmatzis, Ph.D., Stephen J. Itturria, Ph.D.). Core 4: Clinical Follow-up Core (Brian J. Davis, M.D., Mike Blute M.D., Patrick A. Burch, M.D., Thomas M. Pisansky, M.D.). Core 5: Biostatistics Core (Daniel J. Sargent, Ph.D., Susan Geyer, Ph.D., Erik J. Bergstrahl, M.S.). A Developmental Research Program has been established to explore opportunities for innovative research and a Career Development Program has been organized to facilitate young investigators to establish independence in prostate cancer translational research. The SPORE structure provides the ideal mechanism to focus and integrate the discovery efforts of investigators and to optimally utilize the clinical resources of the Mayo Clinic practice to make meaningful advances in the management of prostate cancer.